NICE Backs PTC’s gene therapy for ultra-rare pediatric diseaseTherapeuticsThe gene therapy has yet to be approved in the U.S. PTC expects to submit a Biologics License Application (BLA) to the FDA in the first half of 2023, the company announced. Read more March 24, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/10/PTC_Therapeutics-logo.jpg 450 653 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-03-24 10:43:502023-03-24 10:44:20NICE Backs PTC’s gene therapy for ultra-rare pediatric disease